Is it just me or was this strategy presentation extremely light on detail?
Don't get me wrong, I agree with the priorities they outlined, but just jotting down dot points like 'trade spend and pricing discipline' and 'tighter inventory management' doesn't inspire a lot of confidence for me. These are obviously important goals in relation to the China market but they are just that, goals, without any indication of what will tangibly change in order to achieve those goals.
I didn't listen to the accompanying presentation so perhaps there was much more said in-person than there is in the presentation slides.
There is no mention of daigou channel, which is good as they should be pivoting hard away from it, but the lack of explicitly mentioning such a pivot makes me suspect that the outlook could still be conditional on daigou resellers.
The USA business is the most impressive aspect of what BUB has got going on currently. The fact they are already amidst the clinical trials testing phase of the FDA process is commendable. I think they are probably quite far ahead of other foreign competition in this respect.
So the USA business gets a big tick from me whereas the China Reset sounds more like a wish list at this stage.
BUB Price at posting:
21.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)